Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis

被引：2
|
作者：
Cheung, Matthew C.
Amitai, Irina
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140577
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)
    O'Brien, Susan M.
    Jones, Jeffrey A.
    Furman, Richard R.
    Coutre, Steven E.
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie A.
    Sharman, Jeff P.
    Wierda, William G.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Johnson, Amy J.
    Tran, Anh
    Zhou, Cathy
    Bilotti, Elizabeth
    James, Danelle F.
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S206
  • [22] Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
    Ghosh, Nilanjan
    Sharman, Jeff P.
    Barrientos, Jacqueline C.
    Brander, Danielle
    Gutierrez, Meghan
    Wu, Linda
    Qureshi, Zaina P.
    Upasani, Sandhya
    Naganuma, Maoko
    Mato, Anthony R.
    BLOOD, 2022, 140 : 7047 - 7049
  • [23] Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Aarup, Kathrine
    Enggaard, Lisbeth
    Pedersen, Robert Schou
    Thomsen, Rasmus Heje
    Bergmann, Olav Jonas
    Frederiksen, Mikael
    Christiansen, Ilse
    Nielsen, Tine
    Frederiksen, Henrik
    Niemann, Carsten Utoft
    Andersen, Michael Asger
    BLOOD, 2019, 134
  • [24] Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Analysis of 2028 patients
    Tsimberidou, A. M.
    Wen, S.
    O'Brien, S.
    McLaughlin, P.
    Wierda, W. G.
    Kantarjian, H.
    Lerner, S.
    Strom, S.
    Freireich, E. J.
    Medeiros, L.
    Keating, M. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 196 - 196
  • [25] Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Kipps, Thomas J.
    Fraser, Graeme
    Coutre, Steven
    Brown, Jennifer R.
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Byrd, John C.
    O'Brien, Susan M.
    Dilhuydy, Marie-Sarah
    Devereux, Stephen
    Jaeger, Ulrich
    Moreno, Carol
    Cramer, Paula
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    Mahler, Michelle
    Salman, Mariya
    Cheng, Mei
    Londhe, Anil
    Ninomoto, Joi
    Howes, Angela
    James, Danelle
    Hallek, Michael
    CANCER RESEARCH, 2017, 77
  • [26] Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
    Abrisqueta, Pau
    Loscertales, Javier
    Jose Terol, Maria
    Ramirez Payer, Angel
    Ortiz, Macarena
    Perez, Inmaculada
    Cuellar-Garcia, Carolina
    Fernandez de la Mata, Margarita
    Rodriguez, Alicia
    Lario, Ana
    Delgado, Julio
    Godoy, Ana
    Arguinano Perez, Jose Ma
    Berruezo, Ma Jose
    Oliveira, Ana
    Hernandez-Rivas, Jose-Angel
    Dolores Garcia Malo, Maria
    Medina, Angeles
    Garcia Martin, Paloma
    Osorio, Santiago
    Baltasar, Patricia
    Fernandez-Zarzoso, Miguel
    Marco, Fernando
    Vidal Mancenido, Ma Jesus
    Smucler Simonovich, Alicia
    Lopez Rubio, Montserrat
    Jarque, Isidro
    Suarez, Alexia
    Fernandez Alvarez, Ruben
    Lancharro Anchel, Aima
    Rios, Eduardo
    Losada Castillo, Maria del Carmen
    Perez Persona, Ernesto
    Garcia Munoz, Ricardo
    Ramos, Rafael
    Yanez, Lucrecia
    Bello, Jose Luis
    Loriente, Cristina
    Acha, Daniel
    Villanueva, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : E985 - E999
  • [27] Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Meta-Analysis of Randomized Controlled Trials
    Zhang, Shijia
    Sanchez, Larysa
    Liu, Jieqi
    Chang, Victor
    Goldberg, Stuart L.
    BLOOD, 2016, 128 (22)
  • [28] Ibrutinib in patients with autoimmune cytopenias and previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) from the phase 3 RESONATETM study
    Montillo, Marco
    O'Brien, Susan
    Tedeschi, Alessandra
    Byrd, John
    Dearden, Claire
    Gill, Devinder
    Brown, Jennifer
    Barrientos, Jacqueline
    Mulligan, Stephen
    Furman, Richard
    Cymbalista, Florence
    Plascencia, Clara
    Chang, Stephen
    Hsu, Emily
    James, Danelle
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2015, 56 : 150 - 151
  • [29] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial
    Cramer, Paula
    Chanan-Khan, Asher
    Fraser, Graeme
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Barlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Masha
    Howes, Angela
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2015, 56 : 93 - 94
  • [30] Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
    Finnes, Heidi D.
    Chaffee, Kari G.
    Call, Timothy G.
    Ding, Wei
    Kenderian, Saad S.
    Bowen, Deborah A.
    Conte, Michael
    McCullough, Kristen B.
    Merten, Julianna A.
    Bartoo, Gabriel T.
    Smith, Matthew D.
    Leis, Jose
    Chanan-Khan, Asher
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Shanafelt, Tait D.
    Parikh, Sameer A.
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1376 - 1383
12345